Pneumococcal conjugate vaccine : CCConsensus on the current situation;Pneumokokkenkonjugatimpfstoffe : Expertenkonsensuspapier zum aktuellen Stand der Dinge

Monatsschrift fur Kinderheilkunde

Volumn 157, Issue 12, 2009, Pages 1252-1256

  Adam, D ^a   Busse, A ^a  

^a Kinder und Jugendarztpraxis ^*  (Germany)

Author keywords

Conjugate vaccine; Immunogenicity; Pneumococci; Prevention; Serotypes

Indexed keywords

ANTIBIOTIC AGENT; PNEUMOCOCCAL CONJUGATE VACCINE 13; PNEUMOCOCCAL CONJUGATE VACCINE 7; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACUTE OTITIS MEDIA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; MENINGITIS; PNEUMOCOCCAL INFECTION; PNEUMONIA; SEPTICEMIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

EID: 77249106571     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-009-2132-5     Document Type: Conference Paper

References (34)

1. Adam D, Fehnle K (2008) Safety and effectiveness against respiratory tract infections for pneumococ¬cal conjugate vaccine co-administered with routi¬ne vaccine combinations. Vaccine 26:5944-5951
2. Ansaldi F, Sticchi L, Durando P et al (2008) Decline in pneumonia and acute otitis media after the in¬troduction of childhood pneumococcal vaccinati¬on in Liguria, Italy. J Int Med Res 36:1255-1260
3. Black S, Shinefield H, Fireman B et al (2000) Effi¬cacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Nor¬thern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19:187-195
4. Black S, Shinefield H, Baxter R et al (2004) Post¬licensure surveillance for pneumococcal inva¬sive disease after use of heptavalent pneumococ¬cal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23:485-489
5. CDC (2005) Direct and indirect effects of routi¬ne vaccination of children with 7-valent pneumo¬coccal conjugate vaccine on incidence of inva¬sive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54:893-897
6. CDC (2009) Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine - United States, 1997-2006. MMWR Morb Mortal Wkly Rep 58:1-4
7. Claes C, Reinert RR, Schulenburg JM von der (2009) Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany con¬sidering herd immunity effects. Eur J Health Econ 10:25-38
8. Eskola J, Kilpi T, Palmu A et al (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344:403-409 (Pubitemid 32128672)
9. Grijalva CG, Nuorti JP, Arbogast PG et al (2007) De¬cline in pneumonia admissions after routine child¬hood immunisation with pneumococcal conjuga¬te vaccine in the USA: a time-series analysis. Lan¬cet 369:1179-1186
10. Grimprel E, Laudat F, Baker SA et al (2009) Safe¬ty and immunogenicity of a 13-valent pneumo¬coccal conjugate vaccine given with routine pedi¬atric vaccination to healthy children in France. Eu¬ropean Society for Paediatric Infectious Diseases (ESPID), Brussels
11. GSK (2009) Fachinformation Synflorix (Stand: März). GlaxoSmithKline, München
12. Hsu HE, Shutt KA, Moore MR et al (2009) Effect of pneumococcal conjugate vaccine on pneumococ¬cal meningitis. N Engl J Med 360:244-256
13. Isaacman D, McIntosh D, Reinert RR (2009) Bur¬den of invasive pneumococcal disease and sero¬type distribution among Streptococcus pneumo¬niae isolates in young children in Europe: impact of the seven-valent pneumococcal conjugate vac¬cine and considerations for future conjugate vacci¬nes. Int J Infect Dis Aug 21. [Epub ahead of print]
14. Kieninger DM, Kueper K, Steul K et al (2008) Safe¬ty and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given as a 4-dose series with routine vaccines in healty in¬fants and toddlers. Interscience Conference on An¬timicrobial Agents and Chemotherapy (ICAAC), Washington
15. Kries R von, Hermann M, Al-Lahham A et al (2002) Will the 7-valent pneumococcal vaccine have a si¬milar impact on all invasive pneumococcal infec¬tions in children in Germany as in the Kaiser Per¬manente Trial? Eur J Pediatr [Suppl 2] 161:S140-S143
16. Kyaw MH, Lynfield R, Schaffner W et al (2006) Ef¬fect of introduction of the pneumococcal conjuga¬te vaccine on drug-resistant Streptococcus pneu¬moniae. N Engl J Med 354:1455-1463
17. Lexau CA, Lynfield R, Danila R et al (2005) Chan¬ging epidemiology of invasive pneumococ¬cal disease among older adults in the era of pe¬diatric pneumococcal conjugate vaccine. JAMA 294:2043-2051
18. Lloyd A, Patel N, Scott DA et al (2008) Cost-effec¬tiveness of heptavalent conjugate pneumococ¬cal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ 9:7-15
19. Lloyd A, Patel R, Kuchenbecker U et al (2009) The cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) compared to 7-valent pneumococcal conjugate vaccine (PCV7) for child¬hood vaccination in Germany. European Society for Paediatric Infectious Diseases (ESPID), Brussels
20. Moore MR (2009) Rethinking replacement and re¬sistance. J Infect Dis 199:771-773
21. Palmu AA, Verho J, Jokinen J et al (2004) The se¬ven-valent pneumococcal conjugate vaccine re¬duces tympanostomy tube placement in children. Pediatr Infect Dis J 23:732-738
22. Poehling KA, Talbot TR, Griffin MR et al (2006) Inva¬sive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295:1668-1674
23. Reinert RR (2005) Epidemiologie, Diagnose und Therapie von Infektionskrankheiten. Positions¬papier, erstellt unter Federführung des Natio¬nalen Referenzzentrums für Streptokokken (Prof. Dr. med. Ralf René Reinert). Chemotherapie J 14(S23):1-17
24. Rose M, Zielen S (2009) Impact of infant immuni¬zation programmes with pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines 8(10):1351-2164
25. Rueckinger S, Van der Linden M, Reinert RR et al (2009) Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27:4136-4141
26. Strutton DR, Kuchenbecker U, Hwang S et al (2009) Impact of 13-valent pneumococcal conjugate vac¬cination on costs and outcomes in Germany and the United States. European Society for Paediatric Infectious Diseases (ESPID), Brussel
27. Van der Linden M, Reinert RR (2008) Surveillance of IPD in children in Germany 2004-2008, before and after the introduction of the national immu¬nization program for PCV7. International Sympo¬sium on Pneumococci & Pneumococcal Diseses (ISPPD), Reykjavik
28. Van der Linden M, Imoehl M, Kries R von et al (2009) Epidemiologie invasiver Pneumokok¬kenerkrankungen bei Kindern in Deutschland von 1997-2009, Effekte der Einführung der Pneumo¬kokken Konjugatimpfung. 1. Nationale Impfkonfe¬renz, Mainz
29. Van der Linden M, Imoehl M, Kries R von et al (2009) National immunization program for Preve¬nar (PCV7) results in reduction of incidence of IPD in german children. European Society for Paedia¬tric Infectious Diseases (ESPID), Brussels
30. Van der Linden M, Reinert RR, Imoehl M (2009) In¬vasive Pneumokokken-Erkrankungen bei Erwach¬senen in Deutschland; Mögliche Herdenimmuni¬tätseffekte nach Einführung der Pneumokokken- Konjugatimpfung bei Kindern. 1. Nationale Impf¬konferenz, Mainz
31. Vesikari T, Wysocki J, Chevallier B et al (2009) Im¬munogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 28:S66-S76
32. Vestrheim DF, Lovoll O, Aaberge IS et al (2008) Ef¬fectiveness of a 2+1 dose schedule pneumococ¬cal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26:3277-3281
33. Whitney CG, Pilishvili T, Farley MM et al (2006) Ef¬fectiveness of seven-valent pneumococcal con¬jugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:1495-1502
34. Zhou F, Shefer A, Kong Y et al (2008) Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 121:253-260